Aims: To examine the outcomes of the treatment with insulin glargine 100 U/mL (IGlar-100) in newly identified subgroups of type 2 diabetes mellitus (T2DM).
Methods: Participants with insulin-nave T2DM (n = 2684) from nine randomised clinical trials that started IGlar-100 were pooled and put into subgroups called "Mild Age-Related Diabetes (MARD)," "Mild Obesity Diabetes (MOD)," "Severe Insulin Resistant Diabetes (SIRD)," and "Severe Insulin Deficient Diabetes (SIDD)" based on their age at diagnosis, HbA1c, FPG, hypoglycemia, insulin portion, and body weight were examined at standard and 24 weeks.
Results: MARD 15.3 percent (n = 411), MOD 39.8 percent (n = 1067), SIRD 10.5 percent (n = 283), and SIDD 34.4 percent (n = 923). After 24 weeks, the subgroups' adjusted least square mean reductions in HbA1c from baseline (8.0–9.6%) were comparable (1.4–1.5%). SIDD was more averse to accomplish HbA1c < 7.0 % (OR: 0.40 [0.29, 0.55]) as opposed to MARD. While the last IGlar-100 portion (0.36 U/kg) in MARD was lower than in different subgroups (0.46-0.50 U/kg), it had the most noteworthy hypoglycemia risk. SIRD had least hypoglycemia risk and SIDD showed most prominent body weight gain.
Conclusion: IGlar-100 brought down hyperglycemia likewise in all T2DM subgroups, yet level of glycemic control, insulin portion, and hypoglycemia risk varied between subgroups.
